Abstract

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an important therapeutic advancement for the treatment of Parkinson's disease (PD). Its beneficial effects on motor functions are well established, but its cognitive, affective, and behavioral sequelae come increasingly into the focus of the medical and ethical discussion. In order to evaluate whether these side effects may counteract the beneficial effects of STN DBS on the patient's quality of life, we classify them along the dimensions “measurement complexity” and “weighted life-impact.” Based on this analysis, we discuss their ethical impact and propose guidelines for the clinical setting of STN DBS.